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Abstract Societies are constantly challenged to
develop policies around the introduction of new
technologies, which by their very nature contain great
uncertainty. This uncertainty gives prominence to
varying viewpoints which are value laden and have the
ability to drastically shift policy. The issue of
nanotechnologies is a prime example. The labelling
of products that contain new technologies has been
one policy tool governments have used to address
concerns around uncertainty. Our study develops
evidence regarding opinions on the labelling of
products made by nanotechnologies. We undertook a
computer-assisted telephone (CATI) survey of the
Australian public and those involved in nanotechnolo-
gies from the academic, business and government
sectors using a standardised questionnaire. Analysis
was undertaken using descriptive and logistic regres-
sion techniques. We explored reluctance to purchase
as a result of labelling products which contained
manufactured nanomaterials both generally and across
five broad products (food, cosmetics/sunscreens,
medicines, pesticides, tennis racquets/computers)
which represent the broad categories of products
regulated by differing government agencies in Aus-
tralia. We examined the relationship between reluc-
tance to purchase and risk perception, trust, and
familiarity. We found irrespective of stakeholder,
most supported the labelling of products which
contained manufactured nanomaterials. Perception of
risk was the main driver of reluctance to purchase,
while trust and familiarity were likely to have an
indirect effect through risk perception. Food is likely
to be the greatest product impacted by labelling. Risk
perception surrounding nanotechnologies and label
‘framing’ on the product are key issues to be addressed
in the implementation of a labelling scheme.
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Introduction
Societies are constantly faced with a range of risks and
are challenged to develop the appropriate policy
responses. Part of the challenge lies with the fact that
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the management of risks are value laden, and their
assessment is likely to be multidisciplinary in nature
(Aven and Zio 2014; Hansson and Aven 2014). The
differing values and interpretations of ‘risk’ both
within disciplines (Andretta 2014; Aven and Zio 2014)
and more broadly society as a whole can lead to
contrasting positions. The balancing of these positions
is how policy is formed; however, a sudden shift in the
power of one position can lead to significant regula-
tory and policy reform (Hood et al. 2001) with
potentially undesirable consequences. Therefore,
understanding societal perceptions of risk and risk
values is important to ensure a balanced policy
approach.
Nanotechnologies is described as a collective term
for a range of technologies, techniques and processes
that involve the manipulation of matter at the
nanoscale—the sizes range from approximately 1
nanometre to 100 nanometres (Australian Office of
Nanotechnology 2007), and is a new technology being
introduced into society. Past experiences of introduc-
ing new technologies into society has highlighted the
importance of how the technology is introduced. The
introduction when poorly done, as was the case for
genetically modified organisms (GMO) into Europe,
has led to societal rejection of the technology (Devos
et al. 2006; Vogel 2012). Concerns have been raised
that the introduction of nanotechnologies into society
could follow the same path as that of GMO in Europe
(Duncan 2011; Siegrist 2010). To avoid this fate,
many have prompted calls for greater public engage-
ment and early consideration of regulatory tools such
as labelling for nanotechnologies (Bostrom and
Lo¨fstedt 2010; D’Silva and Bowman 2010; Siegrist
2010).
Labelling is a tool that easily conveys information
to consumers so they can make an informed choice
with regard to a product (D’Silva and Bowman 2010).
Support for the labelling of nanotechnology-based
products centres on societal rights that will ultimately
bring about consumer acceptance of nanotechnolo-
gies. Specifically, it is argued that every citizen has a
right to knowwhat they are purchasing. This right then
provides them with freedom of choice to purchase or
not to purchase the product. This increased trans-
parency will lead to greater trust between consumer
and producer, which will ultimately lead to greater
acceptance and less resentment of nanotechnology-
based products. It is also argued that labelling allows
consumers to become aware, and through this aware-
ness, informed about nanotechnology-based products.
Finally, labelling provides the ability for nanotech-
nology-based products to be tracked through society
allowing researchers and governments the increased
ability to determine and control for any adverse effects
they may have on society (Adler 2010; Brown and
Kuzma 2013; D’Silva and Bowman 2010; Grue`re
2011; Morris et al. 2011).
Mandatory consumer product labelling has always
been a point of contention between regulatory agencies,
businesses and the public (D’Silva and Bowman 2010).
Arguments against the labelling of nanotechnology-
based products centre on misinterpretation of label
meaning and the complications of implementing a
labelling scheme. Specifically, arguments include neg-
ative perceptions (creating stigma, fear, reduced public
acceptance and disinvestment), additional costs to
implement labelling, potential trade barriers between
the country that requires labelling and those who do not,
shifting the responsibility of determining the accept-
ability of the risk to the consumer because now they
have a choice, and public apathy. Complications of
implementation of a scheme include a clear definition
of nanoproducts, having creditable and accurate detec-
tion tools to enforce the system, having clear guidance
regarding thresholds for accidental (and natural) nano-
material contamination, and clear guidance around a
product that may not contain nanoproducts, but which
has been manufactured by nanoproducts (Adler 2010;
Brown and Kuzma 2013; D’Silva and Bowman 2010;
Grue`re 2011; Stamm 2011). Despite these challenges,
Bowman et al. (Bowman et al. 2010) and Stamm
(Stamm 2011) provide some insight into how this
regulation is undertaken in the EU, with the EU
(Aschberger et al. 2014), New Zealand (New Zealand
Government 2012) and Australia (Australian Govern-
ment 2011) requiring compulsory labelling of certain
nanoproducts.
The few peer-reviewed studies of public percep-
tions of labelling products containing manufactured
nanomaterials have shown the public is generally
supportive of their labelling, regardless of origin of
population studied (Brown and Kuzma 2013; IPSOS
Social Research Institute 2012; Throne-Holst and Rip
2011). Australian studies have found that the public is
concerned about the lack of potential regulations/
testing for labelling (Market Attitude Research Ser-
vices 2011) and supportive of government funding to
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rectify this (IPSOS Social Research Institute 2012). In
a Norwegian study, participants highlighted concern
regarding a regulatory framework that did not fully
cover nanoproducts (Throne-Holst and Strandbakken
2009). This study drew out three key concerns:
transparency (about the motives and criteria for
labelling), accountability (those who set up the
programme need to be accountable for it) and
responsibility (someone needs to be responsible for
it) (Throne-Holst and Rip 2011; Throne-Holst and
Strandbakken 2009). A study in the United States
showed the public have concerns regarding regulation,
although they believed they would have little influence
in the development of such regulation (Brown and
Kuzma 2013). This study drew out three themes:
‘‘Labelling Preference’’—most were in support for it
and suggested it be on the front side of packaging;
‘‘Label Use Moderators’’—the label will require
explanation for the public to use it correctly; and
‘‘Information Sources’’—two dichotomous themes
emerged, institutionally based and personally based
information sources, i.e. some saw it was the respon-
sibility of government and industry to provide the
education, while others saw it as a personal respon-
sibility. The study further found that participants rely
heavily on past experiences of product labelling in
order to inform opinions on nanolabelling and con-
cluded that consumer acceptance of the product relates
to its ultimate success (Brown and Kuzma 2013).
A Swiss study examined the influence the labelling of
sunscreen bottles had on the perceptions of risk and
found that the label significantly increased risk and
reduced benefit perception (Siegrist and Keller 2011).
However, in this study, it could be argued that the
‘framing’ of the labelling could have biased the
perceptions, be that its size, shape and position on the
bottle, was alarming in itself. In contrast, mandatory
labelling of consumer cosmetics within Europe has
resulted in very little societal response (Frewer et al.
2014).
In this paper, we develop evidence currently
lacking in the international published literature. That
is, different stakeholder perceptions of labelling
products made from nanotechnologies along with the
factors associated with these perceptions. We explore
the relationships between Australian public, aca-
demic, government and business risk and labelling
perceptions around nanotechnologies and investigate
the potential advantages, barriers and impacts of
labelling products containing manufactured nanoma-
terials. We undertake this on five generic product-
based items (food, cosmetics/sunscreens, medicine,
pesticides, and tennis racquet/computers) which rep-
resent the broad categories of products regulated by
differing government agencies in Australia (Capon
et al. 2013). We have a number of hypotheses. The
public perception of risk from nanoparticles is much
higher than that expressed by other stakeholders
(Capon et al. 2015a; Siegrist et al. 2007). Also a
person’s risk perception can influence their purchasing
habits with evidence that a negative risk perception is
associated with negative purchasing habits (Verbeke
et al. 2007; Yeung andMorris 2001). Accordingly, our
first two hypotheses are that the public will be
significantly less likely to buy a product if it has a
label on it stating it contains nanomaterials than any
other stakeholder. Further, those in the public who
perceive nanoparticles as a risk in a particular generic
product will be significantly less likely to buy that
product if it has a label stating it contained manufac-
tured nanoparticles. When faced with unresolved risk,
consumers will draw on a range of strategies including
endorsement from trusted sources (Yeung and Morris
2001). Therefore, our third hypothesis is that those
who have less trust in the health department, scientists,
politicians and journalists to keep them safe from any
possible adverse health effects of nanomaterials will
be significantly less likely to buy a product if it has a
label on it stating it contains nanomaterials. Low
familiarity of nanotechnology has been associated
with the increased perception of risk of manufactured
nanomaterials (Capon et al. 2015a). Subsequently, our
fourth hypothesis is that those who report lower
familiarity with nanotechnology will be significantly




InMarch 2013, we undertook a nationally representative
cross-sectional household survey (n = 1355) of adult
individuals using computer assisted telephone inter-
viewing (CATI) landline (response rate = 34 %) and
mobile phone technologies (response rate = 19 %).
Sampling was based on random selection from a
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stratified area probability sample of private dwellings
and mobile phone users. All participants were recruited
through random digit dialling sampling with landline
respondents selected through the ‘last birthday tech-
nique’. Sample weights accounted for the probability of
selection, calibrated by age and gender (but not for
jurisdictional strata) to the June 2012 Australian Bureau
of Statistics (ABS) Estimated Resident Population.
From May–July 2013, we undertook a similar
survey of academic, business and government stake-
holders using CATI landline technology. Academic
and business contacts were identified if they belong to
the Australian Nanotechnology Network members list
or are named in the 2011 Nanotechnology—Aus-
tralian Capability Report 4th edition. Government
contacts were identified through snowballing tech-
nique instigated by one of the authors who is actively
involved in the area. A total of 1732 academic, 69
business and 45 government contacts were identified.
All identified business (response rate = 36 %,
n = 21) and government contacts (response
rate = 48 %, n = 19) were approached, while a
simple random sample of academic contacts (response
rate = 33 %, n = 301) through random sorting and
selection was undertaken.
Survey design/measures
The survey was developed, from previous studies
(IPSOS Social Research Institute 2012; McAllister
2011; Retzbach et al. 2011; TNS Opinion and Social
2010) and had cognitive testing on 10 random
individuals of varying ages and gender, following
Australian Bureau of Statistics guidelines (Population
Survey Development 2001). Final survey measures
were chosen based on cognitive understanding and
easing of respondent fatigue and subject to expert
review. Common survey questions were repeated
verbatim across all surveys and in the same order to
ensure comparability of answers, and order of ques-
tions within a topic were randomised to avoid ordering
effects. Participants were given an introduction to
nanotechnology and manufactured nanomaterials,
presented in a neutral fashion to minimise any bias.
They were told ‘‘Nanotechnology is science at a very
small scale and refers to a new array of devices and
materials whose key parts are 10,000 times smaller
than the width of a human hair. Working at this scale
allows science researchers to create new materials and
products’’, ‘‘Manufactured nanomaterials are the
minute particles produced from nanotechnology. They
are found in over 1000 products on the world market
today including some food containers, cosmetics and
sunscreens, clothing, sporting goods and computers.’’
The primary outcome variables of interest for mea-
suring reluctance to purchase due to labelling was
based on the response to the questions ‘‘If a (food
product), (sunscreen), (non-prescription (off the shelf)
medicine), (pesticide), (consumer good such as a
tennis racquet or computer) had a label on it stating it
contains nanomaterials would you be less likely to buy
it?’’. Answers were binary: yes/no.
Other variables of interest included basic demo-
graphics (age, gender), corresponding ‘nano risk’,
general opinion on labelling and ‘nano trust’ (of the
health department, scientists, journalists and politi-
cians). The public survey included ‘nano familiarity’,
while the academic, business, government survey
included open-ended questions on challenges and
advantages of labelling products containing manufac-
tured nanomaterials.
Corresponding ‘nano risk’ was determined in
response to the questions ‘‘Overall, in my opinion,
manufactured nanomaterials are a risk if they are put
in the food I eat’’ or ‘‘Overall in my opinion, putting
manufactured nanomaterials into products such as
(cosmetics and sunscreens) (medicines) (pesticides)
(tennis racquets and computers) is a risk.’’ and was
categorised into agree versus disagree. Respondents
were asked to consider both risks AND benefits when
answering these questions.
General opinion on labelling was determined in
response to the following question ‘‘Some people say
that we should put labels on products to let them know
that they contain manufactured nanomaterials. What
do you think? Do you think they should be labelled or
they should not be labelled?’’. Answers were binary:
yes/no.
‘Nano trust’ was determined in response to the
question ‘‘In general how much do you trust X to keep
you safe from any possible health effects of nanoma-
terials? Would you say you have no trust at all, a little
trust, moderate trust, a lot of trust or absolute trust?’’.
These answers were then collapsed into a three-point
‘low’ (no—a little), ‘moderate’ (moderate) and ‘high’
(a lot—absolute) response.
‘Nano familiarity’ was based on a composite of
three questions. ‘‘Before today, had you heard of the
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term ‘Nanotechnology’’’ (Yes/No), if yes ‘‘Have you
ever talked about nanotechnology with anyone before
today?’’, ‘‘Have you ever searched for information
about nanotechnology?’’ (Yes, frequently; Yes, occa-
sionally; Yes, only once or twice; No, never). No
familiarity (n = 398) was based on a ‘‘no’’ answer to
the first question, moderate familiarity (n = 422) on a
‘‘yes’’ answer to all questions, while some familiarity
(n = 528) was the composite of the remaining
answers.
Challenges and advantages with labelling were
determined from two open-ended questions. ‘‘Do you
see any challenges or problems with labelling products
which contain manufactured nanomaterials? (‘Yes’/
‘No’). If ‘Yes’ ‘‘Can you please tell me what you see
are the challenges or problems with labelling products
which contain manufactured nanomaterials?’’. ‘‘Do
you see any advantages or positive outcomes with
labelling products which contain manufactured nano-
materials?’’ (‘Yes’/‘No’). If ‘Yes’ ‘‘Can you please
tell me what you see are the advantages or positive
outcomes with labelling products which contain
manufactured nanomaterials?’’.
The final survey instrument received ethics
approval from the University of Sydney Ethics
Committee. (2012/1841).
Statistics
Data were analysed using SAS Enterprise Guide 6.1
with the Proc Survey function. The Proc Survey
function allows analysis to be corrected for weighting
and stratified sample design to provide prevalence
estimates. Statistical significance between all four
stakeholders was determined at a P value ofB0.05 and
is reported as such in this paper. For the analysis of
public data, only a secondary P value of B0.01 was
also considered to account for multiple comparisons.
The sample size for business and government respon-
dents were not large enough to consider the P value of
B0.01.
Prevalence estimates of reluctance to purchase due
to labelling and risk perceptions were analysed using
the descriptive statistics of proportions.
Thematic analysis was undertaken by one coder on
the open-ended questions regarding the challenges and
advantages of labelling products containing manufac-
tured nanomaterials to systematically identify the
scope of issues. Themes were identified on a subset of
90 answers and examined across all answers. Where a
subsequent theme was identified outside the subset of
90 answers, this theme was then examined across the
whole dataset.
Two-by-two table analysis was undertaken to
determine associations between reluctance to pur-
chase due to labelling and ‘nano risk’ for the public
survey data.
To examine the relationship between stakeholder
groups and reluctance to purchase, an unadjusted
logistic model was used for comparing reluctance to
purchase each product type (5) across the four
stakeholder groups. In addition, the same logistic
models were adjusted for ‘nanorisk’. The logistic
models contained an event category equal to ‘yes’, for
comparing the proportions that were less likely to buy
(reluctant to purchase) between groups. The public
were used as the reference group, where a value less
than 1 signalled a lower proportion that were less
likely to buy than the public and a value greater than 1
a higher proportion that were less likely to buy than the
public.
To examine the relationship between reluctance to
purchase by the public and trust the public have in all
four trust actors an unadjusted logistic model was used
for comparing reluctance to purchase each product
type (5) and trust in each actor (4). In addition, the
same logistic models were adjusted for ‘nanorisk’, age
and gender. Finally, examination of the relationship
between reluctance to purchase by the public and
familiarity the public have with nanotechnology was
undertaken using an unadjusted logistic model to
compare reluctance to purchase each product type (5)
between the three levels of familiarity. These models
were then adjusted for ‘nanorisk’, age and gender.
All variables were retained in all adjusted logistic
regression models as these variables were central to
the purpose of the study (Agresti 2014). The Wald test
was used to determine statistical significance, and
significant effects are also indicated with odds ratio
confidence intervals that do not cross the value of 1.
Results
Overview
In this study, we found that a substantial majority of
public (95 %, CI 93–96 %), academic (83 %, CI
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79–88 %), government (71 %, CI 46–95 %) and
business (68 %, CI 45–91 %) respondents believed
we should put labels on products to let people know
they contain manufactured nanomaterials. For the
public, the product most likely to be affected by
labelling was food (73 % less likely to buy) followed
by off-the-shelf medicines (57 %), cosmetics/sun-
screens (55 %), pesticides (50 %) and computers/
tennis racquets (29 %). This pattern was broadly
consistent for all other stakeholders (Table 1).
Of the 341 academic, government and business
respondents, 233 acknowledged challenges with the
labelling of products containing manufactured nano-
materials. Of the 233, by far the greatest mentioned
challenges were the creation of a negative perception
for nanomaterials (43 %), followed by a lack of
knowledge/understanding of nanomaterials to inter-
pret what the label meant (30 %), and then lack of
information contained on the label to inform the public
of specific risks (27 %). Other challenges raised
included the ambiguity of what nanotechnology is,
including how to define and identify nanomaterials
and the changing nature of nanomaterials through their
lifecycle. A lack of regulation and regulatory frame-
work to oversee the labelling process and the inability
to deliver what the public expect from a labelling
system were also raised, as were problems with
educating the public on what the labels meant,
consumers ignoring the label, the cost of implement-
ing a labelling system and industry resistance.
Of the 341 academic, government and business
respondents, 279 acknowledged advantages with the
labelling of products containing manufactured nano-
materials. Of these 279, the two most mentioned
advantages included consumer awareness/education
of a product that contained nanomaterials (48 %) and
the consumer’s right to know, to have informed choice
and to have input into how the technology should be
released into society (35 %). Other advantages
included increased transparency leading to social trust
and acceptance, and the ability to trace products
through society for safety purposes. Finally, some
believed labelling could give products a competitive
marketing advantage, showing they were advanced
and cutting edge.
Relationship between stakeholder regarding
reluctance to purchase
Unadjusted logistic analysis found the public were
significantly less likely to buy food, sunscreens, off-
the-shelf medicines and pesticides than academic,
business and government stakeholders if those prod-
ucts had a label on them stating they contained
nanomaterials, and significantly less likely to buy
tennis racquets/computers than academic and business
stakeholders if they had a label on them stating they
contained nanomaterials. However, after adjusting for
risk perception, only significant differences remained
between public and academic opinions for food,
sunscreen, pesticides and tennis racquets/computers
(Table 2).
Relationship between the public’s perception
of risk and reluctance to purchase
For all the five products, we found the prevalence of the
population that thought manufactured nanomaterials in
a product were a risk was significantly greater than the
prevalence of those who were reluctant to purchase
Table 1 Prevalence, estimated for each stakeholder, of being less likely to buy the product if that product had nano labelling

























Food 72.8 69.7 75.9 55.4 49.3 61.5 31.6 8.6 54.6 26.3 4.5 48.1
Off the shelf
medicines
57.0 53.6 60.4 35.4 29.9 41.0 25.0 1.2 48.8 10.5 0.0 25.7
Sunscreen 54.7 51.2 58.1 26.8 21.7 31.9 22.2 0.9 43.5 4.8 0.0 14.7
Pesticides 49.3 45.8 52.7 29.8 24.5 35.2 22.2 0.9 43.5 23.8 3.9 43.7
Tennis
racquet/computer
28.9 25.8 32.0 6.5 3.6 9.3 5.3 0.0 16.3 4.8 0.0 14.7
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because of labelling. This is shown in Table 3 which
presents estimated prevalence of the public opinion
regarding risk of manufactured nanomaterials in a
particular product with the estimated prevalence of the
public who reported they would be less likely to buy
that product if it had a label on it stating it contains
nanomaterials.
A positive association was found between a percep-
tion of risk of manufactured nanomaterials in a product
and the reporting of being less likely to buy that product
if it had a label stating it contained manufactured
nanomaterials. This association held for all the five
products (Table 4). Table 4 shows the section of the
public that reported a belief that manufactured nano-
materials in foodwere a risk were 24 times less likely to
buy a food product if it was labelled as containing
nanomaterials. If they thought manufactured nanoma-
terials in cosmetics/sunscreens were a risk, they were
21 times less likely to buy a sunscreen if it had a label on
it stating it contained nanomaterials. Similarly, those
who thought manufactured nanomaterials in medicines
were a risk were 9 times less likely to buy an off-the-
shelf medicine labelled as containing nanomaterials. In
the case of manufactured nanomaterials in pesticides,
Table 2 Logistic analysis of stakeholder perceptions with respect to being less likely to buy because of labelling (yes versus no,
where yes is the event category)
Labelling of product Stakeholder Crude odd ratio 95 % LCI 95 % UCI Adjusted odds ratio 95 % LCI 95 % UCI
Food Public 1 (Ref) 1 (Ref)
Academic 0.3 0.3 0.4 0.6 0.4 0.9
Government 0.2 0.1 0.5 0.5 0.3 1.1
Business 0.1 0.1 0.4 0.7 0.2 2.6
Sunscreen Public 1 (Ref) 1 (Ref)
Academic 0.3 0.2 0.4 0.5 0.3 0.7
Government 0.2 0.1 0.8 0.4 0.1 1.2
Business 0.04 0.01 0.3 0.2 0.02 1.1
Off the shelf medicines Public 1 (Ref) 1 (Ref)
Academic 0.4 0.3 0.6 0.8 0.5 1.1
Government 0.3 0.1 0.8 0.7 0.2 2.2
Business 0.09 0.02 0.4 0.3 0.1 1.2
Pesticides Public 1 (Ref) 1 (Ref)
Academic 0.4 0.3 0.6 0.6 0.4 1.0
Government 0.3 0.1 0.9 0.6 0.2 1.7
Business 0.3 0.1 0.9 0.7 0.4 1.5
Tennis racquet or computer Public 1 (Ref) 1 (Ref)
Academic 0.2 0.1 0.3 0.4 0.2 0.8
Government 0.1 0.02 1.1 0.3 0.04 1.8
Business 0.1 0.02 1.0 0.5 0.1 4.4
Table 3 Prevalence of the
public opinion regarding
risk of nanomaterials in a
product/would be less likely
to buy that product if it had
a label on it
Product Risk (agree) Less likely to buy (yes)
% 99 % LCI 99 % UCI % 99 % LCI 99 % UCI
Food 84.8 81.5 88.1 72.8 68.7 76.8
Cosmetics/sunscreen 72.2 68.0 76.4 54.7 50.2 59.2
Medicines 70.8 66.5 75.0 57.0 52.5 61.5
Pesticides 63.8 59.2 68.4 49.3 44.7 53.8
Tennis racquet/computer 39.6 35.1 44.1 28.9 24.9 33.0
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those who perceived risk were 15 times less likely to
buy a pesticide labelled as containing nanomaterials.
Finally, the smaller group who reported viewing
manufactured nanomaterials in tennis racquets/com-
puters as a risk, were 20 times less likely to buy a
product if it had a label on it stating it contained
nanomaterials.
Relationship between the public’s trust in various
actors and reluctance to purchase
Table 5 shows the results of unadjusted logistic
analyses between the public’s trust in various actors
and reluctance to purchase induced by labelling. A
value less than 1 indicates a greater likelihood to
purchase. It shows that lower trust in scientists was
significantly associated with being less likely to buy
food, sunscreen, off-the-shelf medicines, pesticides
and tennis racquets/computers if it had a label on it
stating it contained nanomaterials. Lower trust in the
health department was significantly associated with
being less likely to buy sunscreen, off-the-shelf
medicines and tennis racquets/computers if it had a
label on it stating it contained nanomaterials. Lower
trust in politicians was significantly associated with
being less likely to buy sunscreen if it had a label on it
stating it contained nanomaterials. However, after
adjusting for risk perception, age and gender, trust the
public had in any actor (health department, scientist,
journalist or politician) was not associated with being
less likely to buy any product, with risk perception
being the main influence of whether people were less
likely to buy or not (P\ 0.01 for all analyses).
Relationship between familiarity and reluctance
to purchase
The unadjusted logistic analysis in Table 6 shows that
when compared to other sections of the public, the
section of the public that reported no familiarity with
nanotechnology were less likely to buy off-the-shelf
medicines and tennis racquets/computers if they were
labelled as containing nanomaterials. However, when
adjusting for risk perception, age and gender, we
found no association between familiarity of nanotech-
nology and being less likely to buy a product if it had a
label on it, while risk perception was significant for all
analyses (P\ 0.01).
Discussion
The examination of stakeholder opinion is key to good
policy as it ensures a holistic consideration of issues
leading to a greater chance of policy acceptance.
Within stakeholder opinion, the considerations of
public opinion for nanotechnology policy develop-
ment has been argued from a normative and substan-
tive perspectives (Katz et al. 2009; Rogers-Hayden
and Pidgeon 2007). Engaging the public contributes to
greater transparency and enhanced democracy. It is
one part of the politics of addressing controversial
questions in a democratic society. All decisions have a
social component, so by considering public opinion, a
more holistic solution is found. In the area of
nanotechnologies where there are many uncertainties
regarding its risks, the public have a legitimate voice.
Table 4 Two-by-two tables of perceived risk of nanomaterials in a product and effect of labelling
Risk (agree/disagree) Less likely to buy (yes) % OR 99 % LCI 99 % UCI
Product
Food (agree) Food 84.2 24.2 12.4 47.1
Food (disagree) Food 18.1
Sunscreen (agree) Sunscreen 73.4 21.1 11.4 39.2
Sunscreen (disagree) Sunscreen 11.5
Medicines (agree) Medicines 73.4 9.2 5.7 14.8
Medicines (disagree) Medicines 23.1
Pesticides (agree) Pesticides 71.3 14.9 8.6 25.9
Pesticides (disagree) Pesticides 14.3
Tennis racquet/computer (agree) Tennis Racquet/computer 62.1 19.5 11.1 34.0
Tennis racquet/computer (disagree) Tennis Racquet/computer 7.8
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This study provides evidence to be used in the
development of nanotechnology policy. It examines
opinions regarding the use of labelling as a risk/policy
tool for nanotechnologies in Australian society and
explores the factors associated with these opinions. It
investigates the differing risk and labelling percep-
tions between the public and academic, government
and business figures involved in nanotechnologies in
Australia.
This study found broad-based support for labelling
of products containing nanomaterials. This is consistent
with other studies (Brown and Kuzma 2013; IPSOS
Social Research Institute 2012; Throne-Holst and Rip
2011) and applied across all stakeholder groups (public,
academia, government, business). There was also
evidence that labelling of products containing nano-
materials is likely to greatly influence consumer-
purchasing behaviour. Food products are the items
most sensitive to labelling, although off-the-shelf
medicines, cosmetics/sunscreens and pesticides are
likely to be affected by labelling. Consumer products
such as tennis racquets and computers may be affected
but not to the extent of the other products.
Our study found the public were less likely to buy a
product labelled as containing nanomaterials than any
other stakeholder, with the exception of tennis rac-
quets/computers. This difference remained for public
versus academic opinion for most products when we
adjusted for risk perception. Thus, we were able to
determine that risk perception alone was not the whole
driver for the dissociation between public and academic
attitudes around reluctance to purchase. Other factors
including an involvement in nanotechnology play a role
in shaping the acceptance of nano-labelled products.
Given the small business and government sample sizes,
it is not surprising that we could not detect a difference
in reluctance to purchase between these stakeholders
and the public after adjusting for risk perception. These
underpowered samples made it unlikely to detect any
true difference, if it existed.
For those members of the public that perceived
nanomaterials as a risk in a product, labelling of that
product indicating nanomaterials was associated with
a reluctance to purchase. Consumers reported they
were up to 24 times less likely to purchase depending
on the product. However, there was a significant
difference in the prevalence of those who were
reluctant to purchase a labelled product when com-
pared to the prevalence of those who thought the same
product was a risk if it contained manufactured
Table 6 Relationship between familiarity and reluctance to purchase adjusted by age, gender and risk perception for public opinion
only (yes versus no, where yes is the event category)














No familiarity 1 (Ref) 1 (Ref)
Some familiarity 0.67 0.40 1.13 0.91 0.47 1.76
Moderate familiarity 0.71 0.41 1.21 1.48 0.73 2.99
Sunscreen
Ref: ‘Yes’
No familiarity 1 (Ref) 1 (Ref)
Some familiarity 0.79 0.50 1.24 1.28 0.70 2.36
Moderate familiarity 0.67 0.42 1.08 1.27 0.69 2.35
Off the shelf medicines
Ref: ‘Yes’
No familiarity 1 (Ref)^ 1 (Ref)
Some familiarity 0.58 0.36 0.91 0.86 0.49 1.51
Moderate familiarity 0.61 0.38 0.99 1.18 0.64 2.16
Pesticides
Ref: ‘Yes’
No familiarity 1 (Ref) 1 (Ref)
Some familiarity 0.65 0.41 1.02 0.98 0.54 1.78
Moderate familiarity 0.67 0.42 1.07 1.12 0.59 2.11
Tennis racquets/computers
Ref: ‘Yes’
No familiarity 1 (Ref)^ 1 (Ref)
Some familiarity 0.49 0.30 0.79 0.60 0.31 1.18
Moderate familiarity 0.35 0.21 0.58 0.54 0.25 1.16
^ Indicates that the overall familiarity factor is significant (P B 0.01)
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nanomaterials (Table 3). This suggests that a propor-
tion of the public who thought the product was a risk
would not be reluctant to purchase the product if it had
a label on it stating it contained nanomaterials.
Our study found reduced trust in scientists and the
health department was associated with a reluctance to
purchase most products. However, after adjusting for
age, gender and perception of risk, trust in any actor
was no longer significant with perception of risk
significant for all associations.
Increased trust in scientists, the health department
and politicians has been associated with reduced
perceptions of risk of manufactured nanomaterials
(Capon et al. 2015a). Generically, work has been
undertaken to determine the directions of the associa-
tion between trust and risk perception. One direction is,
does trust effect your perception of risk that in turn
affects your purchasing behaviour (the casual ‘indirect’
model). The other direction is, does your perception of
risk affect your trust in a regulator, and therefore, there
is no relationship between trust and purchasing
behaviour. Evidence exists for both models (Bronfman
and Va´zquez 2011; Eiser et al. 2002; Poortinga and
Pidgeon 2005). Thus, we conclude that trust in
scientists and the health department are not likely to
have a direct influence over purchasing behaviour,
rather may influence the risk perceptions of the public,
which will then influence their purchasing behaviour.
Therefore, trusted scientists and health department
officials should communicate the risks and benefits of
nanomaterials as a central part of any labelling strategy.
In this way, interpretation of labelling issues that the
public might voice may be indirectly addressed,
allowing appropriate implementation.
The relationship between public familiarity with
nanotechnology and reluctance to purchase appears
similar to that of trust. Lower familiarity was associ-
ated with reluctance to purchase off-the-shelf medici-
nes and tennis racquets/computers. However, after
adjusting for age, gender and perception of risk,
familiarity was no longer significant for any products,
with perception of risk significant for all associations.
Increased familiarity with nanotechnology has been
shown to be significantly associated with a reduced
perception of risk of manufactured nanomaterials
(Capon et al. 2015a). If we assume, like trust, that the
direction of association between familiarity and risk
perception is from familiarity to risk perception (causal
chain), i.e. your familiarity with nanotechnology affects
your risk perception then, like trust, familiarity would
have an indirect effect on purchasing behaviour via risk
perception. Therefore, in theory, increasing familiarity
with nanotechnology could be one way of reducing
possible public stigmatisation of manufactured nano-
materials from a labelling strategy. There are, however,
limitations with the familiarity concept which have
been highlighted elsewhere (Capon et al. 2015a).
This study extracted a number of issues with
labelling, the most prominent regarding community
perception. While some believed labelling would alarm
the community and create a backlash against nanotech-
nology, others expressed labelling would create trust
and social acceptance of nanotechnology. This study
was not designed to determine which viewpoint would
prevail. That would depend on the labelling and
communication strategy that followed it. Further
research into specific labelling messaging and posi-
tioning would need to be undertaken, and it is
recommended that a labelling scheme, if it should be
adopted, should have this research undertaken before
implementation to ensure the labelling met its intended
purpose.
A number of issues raised regarding the feasibility
of a labelling scheme are the same issues that plague
risk regulators in determining the safety of nanoma-
terials. Currently, there is a lack of appropriate or
standard tests to identify or characterise many nano-
materials as well as a lack of toxicological data
(Editorial 2011) and population exposure measure-
ments (Beaudrie and Kandlikar 2011; Canady 2010;
Maynard et al. 2011; Morris et al. 2011;Williams et al.
2010). Therefore, some of the problems surrounding
the implementation of a labelling system are beyond
the labelling scheme itself, rather inherent in intro-
ducing a new technology into society. With regard to
population exposure measures, labelling, as was
raised, is one solution in identifying who in the
community is being exposed to certain manufactured
nanomaterials, along with product registers.
This study has a number of strengths and limitations
which have been covered in previous publications
(Capon et al. 2015a, b) including the small number of
respondents for business and government that pro-
vided little statistical power to determine associations.
The response rate for these groups was similar or
higher than for other groups, as the sample size was a
result of the small number of people employed in these
categories in Australia.
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This study has a number of further limitations.
Firstly, the study examines a consumer’s intention to
buy and not the actual purchasing behaviour. Studies
are inconclusive as to the relationship between intent
and actual purchasing behaviour (Barber and Taylor
2013), and in reality, a number of factors such as price
and choice will affect a consumer’s actual purchasing
behaviour. Secondly, the study is limited by an
inability to survey an actual labelling concept. The
purchasing behaviour of consumers is likely to be
influenced by the construction and positioning of the
label itself. Positioning on front of label in a prominent
location as was undertaken in (Siegrist and Keller
2011) has been shown to increase risk perception and
likely affect consumer purchasing. Labelling placed at
the back of the product, in the ingredient section, with
the word (nano) next to the ingredient as undertaken in
the EU has led to little societal response (Frewer et al.
2014), and it appears to have allowed consumers to
become aware of nanoproducts without creating undue
consumer concern.
Conclusion
How the Australian public perceive the risk of
nanomaterials within a particular product is the main
driver in altering the public’s purchasing habits if that
product is labelled as containing manufactured nano-
materials. The public are significantly more likely to
want labelling of products that contain manufactured
nanomaterials than those involved in nanotechnolo-
gies from academic, business and government sectors;
however, overall support for labelling of products
containing manufactured nanomaterials was high,
irrespective of stakeholder. While risk perception
was an important predictor of reluctance to purchase,
it could not explain the entire difference between
public and academic reluctance suggesting other
factors are also driving the dissociation between
stakeholder views on labelling. Food products are
most likely to be affected by labelling, while consumer
goods such as sporting equipment and computers are
less so. Trust and familiarity were not found to have a
direct effect on reluctance to purchase, but are likely to
have an indirect effect through their association with
risk perception. Consumer perceptions were the most
mentioned reason for implementing and not imple-
menting a labelling scheme. Therefore, understanding
the public’s tolerance of risk for nanotechnologies and
the factors that drive this risk will lead to greater
success in implementing a labelling policy.
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